Heron Therapeutics Inc
NASDAQ:HRTX
Heron Therapeutics Inc
Cash from Financing Activities
Heron Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Heron Therapeutics Inc
NASDAQ:HRTX
|
Cash from Financing Activities
$54.3m
|
CAGR 3-Years
79%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-1%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$211m
|
CAGR 3-Years
74%
|
CAGR 5-Years
59%
|
CAGR 10-Years
24%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$625m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Heron Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
54.3m
USD
Based on the financial report for Mar 31, 2024, Heron Therapeutics Inc's Cash from Financing Activities amounts to 54.3m USD.
What is Heron Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-1%
Over the last year, the Cash from Financing Activities growth was -28%. The average annual Cash from Financing Activities growth rates for Heron Therapeutics Inc have been 79% over the past three years , -31% over the past five years , and -1% over the past ten years .